


FORM PTO-1390 (REV 12-2004)		ATTORNEY DOCKET NUMBER 4439-4030
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (if known, see 37 CFR 1.51) tba 10/524046
INTERNATIONAL APPLICATION PCT/JP2003/010143	INTERNATIONAL FILING DATE 8 August 2003	PRIORITY DATE CLAIMED 8 August 2002
TITLE OF INVENTION Inhibition of Proliferation and Infiltration of Brain Tumor Cells Caused by Expression of AMPA-Type Glutamate Receptor Subunit		
APPLICANT(S) FOR DO/EO/US Seiji Ozawa et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected. (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input checked="" type="checkbox"/> is attached hereto</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unexecuted).</p> <p>10. <input type="checkbox"/> An English translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98, Form 1449, and cited references.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821-1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or Information:</p> <p>International Publication WO 2004/014433 A1, PCT Request, PCT/RO/105, PCT/RO/106, PCT/ISA/202, PCT/ISA/210, PCT/ISA/220, PCT/IB/301, PCT/IB/304, PCT/IB/306, PCT/IB/308.</p>		

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.51)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NO.	
tba 10/524046		PCT/JP2003/010143		4439-4030	
21. The following fees are submitted:					
<input checked="" type="checkbox"/> a) Basic national fee		\$300.00	\$	300	
<input checked="" type="checkbox"/> b) Examination fee		\$200.00	\$	200	
<input checked="" type="checkbox"/> c) Search fee		\$500.00	\$	500	
TOTAL OF ABOVE CALCULATIONS =		\$1,000.00	\$	1,000	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
45 - 100 =	/50 =		x \$250.00	\$	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	13 - 20 =		x \$50.00	\$	
Independent claims	3 - 3 =		x \$200.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00	\$	360
TOTAL OF ABOVE CALCULATIONS =				\$	1,360
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$	1,360
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$
TOTAL NATIONAL FEE =				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	\$
TOTAL FEES ENCLOSED =				\$	1,360
				Amount to be refunded:	\$
				Amount to be charged:	\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$1,360 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. 13-4500 in the amount of \$_____ to cover the above fees.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4439-4030. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p> <p>NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>					
SEND ALL CORRESPONDENCE TO:					
Enter Address Here Kenneth H. Sonnenfeld MORGAN & FINNEGAN, L.L.P. 3 World Financial Center New York, NY 10281-2101			Signature  Kenneth H. Sonnenfeld / Michael A. Willis Name		
Telephone: (212) 415-8700 Facsimile: (212) 415-8701			33,285 / 53,913 REGISTRATION NUMBER		

10/524046

Docket No. 4439-4030
DT01 Rec'd PCT/PTC 07 FEB 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Seiji Ozawa et al.

Group Art Unit: tba

Serial No.: tba

Examiner: tba

Filed: February 7, 2005 (herewith)

For: INHIBITION OF PROLIFERATION AND INFILTRATION OF BRAIN TUMOR
CELLS CAUSED BY EXPRESSION OF AMPA-TYPE GLUTAMATE
RECEPTOR SUBUNIT

EXPRESS MAIL CERTIFICATE

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Express Mail Label No.: EV 498 832 094 US

Date of Deposit: February 7, 2005

I hereby certify that the following attached paper(s) and/or fee

1. Transmittal Letter Concerning Submission Under 35 USC 371 (2 pages + duplicate)
2. Combined Declaration and Power of Attorney, unexecuted (3 pages)
3. Sequence Listing (2 pages), Computer Disk with Sequence Listing, and Statement Under 37 CFR 1.821 (1 page)
4. Application: 36 pages specification, 2 pages claims (11 claims), 1 page abstract, and 6 pages drawings (Figures 1-6)
5. Information Disclosure Statement (2 pages + duplicate), Form 1449, and 3 cited references
6. WO 2004/014433 A1
7. PCT Request, PCT/RO/105, PCT/RO/106, PCT/ISA/202, PCT/ISA/210, PCT/ISA/220, PCT/IB/301, PCT/IB/304, PCT/IB/306, PCT/IB/308.
8. check for \$1,360
9. return postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Michael A. Willis

(Typed or printed name of person mailing papers(s) and/or fee)



(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281-2101

(212) 415-8700 Telephone
(212) 415-8701 Facsimile